Abivax(US:ABVX) Globenewswire·2025-12-15 21:08Core Insights - Abivax reported a significant increase in net loss for the nine months ending September 30, 2025, amounting to EUR 254.1 million, compared to EUR 136.9 million for the same period in 2024, reflecting a rise of EUR 117.3 million [3][5][10] Financial Performance - Total operating income decreased to EUR 4.1 million for the nine months ended September 30, 2025, down from EUR 8.1 million in 2024, a decline of EUR 4.0 million [3][5] - Total operating expenses rose to EUR 178.5 million, with research and development costs increasing by EUR 25.4 million to EUR 133.4 million, primarily due to costs associated with clinical programs for ulcerative colitis and Crohn's disease [3][5][6] - Operating loss increased by EUR 44.2 million to EUR 174.4 million for the nine months ending September 30, 2025, compared to EUR 130.2 million in 2024 [3][5] Cash Position - Cash and cash equivalents as of September 30, 2025, were EUR 589.7 million, a substantial increase from EUR 144.2 million as of December 31, 2024, primarily due to net proceeds from a public offering [5][8] - The company expects its cash runway to extend into Q4 2027 based on its current cash position [10] Shareholder Equity and Financial Position - Total assets increased to EUR 652.1 million as of September 30, 2025, compared to EUR 205.2 million at the end of 2024, reflecting a growth of EUR 446.8 million [5] - Total shareholders' equity rose to EUR 511.2 million from EUR 40.6 million, an increase of EUR 470.7 million [5] Operational Updates - Abivax has been actively presenting updates on its clinical trials, including late-breaking presentations at the 2025 United European Gastroenterology (UEG) Meeting, highlighting the progress of its lead drug candidate, obefazimod [4][10] - The company has made significant advancements in its clinical programs, particularly in ulcerative colitis and Crohn's disease, which are reflected in the increased R&D expenses [3][5][6]